pr domain peptides
TRANSCRIPT
![Page 1: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/1.jpg)
United States Patent [19] Huang
US006069231A
6,069,231 May 30, 2000
[11] Patent Number:
[45] Date of Patent:
[54] PR DOMAIN PEPTIDES
[75] Inventor: Shi Huang, San Diego, Calif.
[73] Assignee: La Jolla Cancer Research Foundation, La Jolla, Calif.
[21] Appl. No.: 08/516,859
[22] Filed: Aug. 18, 1995
Related US. Application Data
[63] Continuation-in-part of application No. 08/399,411, Mar. 6, 1995, Pat. No. 5,831,008, which is a continuation-in-part of application No. 08/292,683, Aug. 18, 1994, abandoned.
[51] Int. Cl.7 .......................... .. C06K 7/06; C06K 14/435
[52] US. Cl. ......................... .. 530/327; 530/300; 530/350 [58] Field of Search ................................... .. 530/300, 324,
530/350
[56] References Cited
PUBLICATIONS
George et al. Macromolecular Sequencing & Synthesis Selected Methods & Applications, pp. 127—149, 1988. Bourne et al., “The GTPase superfamily: conserved struc ture and molecular mechanism.” Nature, 349:117—127
(1991). Boyd et al., “A region in the C—terminus of adenovirus 2/5 Ela protein is required for association With a cellular phosphoprotein and important for the negative modulation of T24—ras mediated transformation, tumorigenesis and metastasis.” EMBO. J. 12:469—478 (1993). Van Cherington et al., “Separation of simian virus 40 large T antigen transforming and origin—binding functions from the ability to block differentiation.” Mol. Cell. Biol., 8:1380—1384 (1988). DeCaprio et al., “SV40 large tumor antigen forms a speci?c complex With the product of the retinoblastoma susceptibil ity gene.” Cell, 54:275—283 (1988). Defeo—Jones et al., “Cloning of cDNAs for cellular proteins that bind to the retinoblastoma gene product.” Nature, 352:251—254 (1991). DoWdy et al., “Physical interaction of the retinoblastoma protein With human D cyclins.” Cell 73:499—511 (1993). Durfee et al., “The retinoblastoma protein associates With the protein phosphatase type 1 catalytic subunit.” Genes Dev., 7:555—569 (1993). Dyson et al., “Adenovirus E1A makes tWo distinct contacts With the retinoblastoma protein.” J. Virol., 66:4606—4611 (1992). EWen et al., “Functional interactions of the retinoblastoma protein With mammalian D—type cyclins.” Cell, 73:487—497 (1993). Ford et al., “Nuclear protein With sequence homology to translation initiation factor eIF—4A.” Nature, 332:736—738
(1988). HarloW et al., “Association of adenovirus early region 1A proteins With cellular polypeptides.” Mol. Cell. Biol., 6:1579—1589 (1986).
Hirling et al., “RNA helicase activity associated With the human p68 protein.” Nature, 339:562—564 (1989). Hu et al., “The regions of the retinoblastoma protein needed for binding to adenovirus E1A or SV40 large T antigen are common sites for mutations.” EMBO J., 9:1147—1155
(1990). Huang et al., “TWo distinct and frequently mutated regions of retinoblastoma protein are required for binding to SV40 T antigen.” EMBO J., 9:1815—1822 (1990). Huang et al., “A cellular protein that competes With SV40 T antigen for binding to the retinoblastoma gene product.” Nature, 350:160—162 (1991). Huang et al., “The retinoblastoma protein region required for interaction With the E2F transcription factor includes the T/ElAbinding and carboXy—terminal sequences.” DNA Cell Biol., 11:539—548 (1992). Kaelin, Jr. et al., “De?nition of the minimal simian virus 40 large TAntigen and adenovirus E1A—binding domain in the retinoblastoma gene product.” Mol. Cell. Biol., 10:3761—3769 (1990). Keller and Maniatis, “Identi?cation and characterization of a novel repressor of [3—interferon gene expression.” Genes Dev., 5:868—879 (1991). Kimelman et al., “Ela regions of the human adenoviruses and of the highly oncogenic simian adenovirus 7 are closely related.” J. Virol, 53:399—409 (1985). M. KoZak, “An analysis of 5‘ noncoding sequences from 699 vertebrate messenger RN .” Nucl. Acids Res. 15:8125—8148 (1987). Krieg and Melton, “Functional messenger RNAs are pro duced by SP6 in vitro transcription of cloned cDNAs.” Nucl. Acids Res., 12:7057—7070 (1984). Lane and Hoef?er, “SV40 large T shares an antigenic determinant With a cellular protein of molecular Weight 68,000.” Nature, 288:167—170 (1980). Lillie et al., “Functional domains of adenovirus type 5 Ela proteins.” Cell, 50:1091—1100 (1987). LudloW et al., “SV40 large T antigen binds preferentially to an under phosphorylated member of the retinoblastoma susceptibility gene product family.” Cell, 56:57—65 (1989). Mihara et al., “Cell cycle—dependent regulation of phospho rylation of the human retinoblastoma gene product.” Sci ence, 246:1300—1303 (1989). E. Moran, “A region of SV40 large T antigen can substitute for a transforming domain of the adenovirus ElAproducts.” Nature, 334:168—170 (1988).
(List continued on neXt page.)
Primary Examiner—Lila Feisee Assistant Examiner—Christine Saoud Attorney, Agent, or Firm—Campbell & Flores LLP
[57] ABSTRACT
The present invention provides PR domain peptides, Which are about 100 to about 120 amino acids in length and contain three highly conserved sequences of about 10 to about 12 amino acids, separated by less conserved sequences of about 20 to about 35 amino acids.
18 Claims, 26 Drawing Sheets
![Page 2: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/2.jpg)
6,069,231 Page 2
OTHER PUBLICATIONS
Moran and Matthews, “Multiple functional domains in the adenovirus E1A gene.” Cell, 48:177—178 (1987). J .R. Nevins, “E2F: a link betWeen the Rb tumor suppressor protein and viral oncoproteins.” Science, 258:424—429 (1992). PaWson and Gish, “SH2 and SH3 domains: from structure to function.” Cell 71:359—362 (1992). Qin et al., “Identi?cation of a groWth suppression domain Within the retinoblastoma gene product.” Genes Dev., 6:953—964 (1992). Quinlan et al., “GroWth factor induction by the adenovirus type 5 E1A 12S protein is required for immortiliZation of primary epithelial cells.” Mol. Cell. Biol., 8:3191—3203 (1988). Quinlan and Douglas, “ImmortiliZation of primary epithelial cells requires ?rst— and second—exon functions of adenovi rus type 5 12S.” J. Virol, 66:2020—2030 (1992). Ren et al., “Identi?cation of a ten—amino acid proline—rich SH3 binding site.” Science, 259:1157—1161 (1993). Saraste et al., “The P—loop—a common motif in ATP— and GTP—binding proteins.” Trends. Biochem. Sci., 15 :430—434 (1990). Scheffner et al., “RNA unWinding activity of SV40 large T antigen.” Cell 57:955—963 (1989). Smith and Ziff, “The amino—terminal region of the aden ovirus serotype 5 E1a protein performs tWo separate func tions When expressed in primary baby rat kidney cells.” Mol. Cell. Biol, 8:3882—3890 (1988). Subramanian et al., “Enhanced ras oncogene mediated cell transformation and tumorigenesis by adenovirus 2 mutants lacking the C—terminal region of E1a protein.” Oncogene, 4:415—420 (1989). Templeton et al., “Nonfunctional mutants of the retinoblas toma protein are characteriZed by defects in phosphoryla tion, viral oncoprotein association, and nuclear tethering.” Proc. Natl. Acad. Sci. USA, 88:3033—3037 (1991). Wang et al., “Identi?cation of speci?c adenovirus E1A N—terminal residues critical to the binding of cellular pro teins and the control of cell groWth.” J. Virol, 67:476—488 (1993). RA. Weinberg, “Tumor suppressor genes.” Science, 254:1138—1146 (1991). Welch and Wang, “A C—terminal protein—binding domain in the retinoblastoma protein regulates nuclear c—Abl tyrosine kinase in the cell cycle.” Cell, 75:779—790 (1993). Whyte et al., “Association betWeen an oncogene and an anti—oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product.” Nature 334:124—129 (1988). Whyte et al., “Cellular targets for transformation by the adenovirus E1A proteins.” Cell, 56:67—75 (1989). Walker et al., “Distantly related sequences in the ot— and [3—subunits of ATP synthase, myosin, kinases and other ATP—requiring enZymes and a common nucleotide binding fold.” Embo J., 1(8):945—951 (1982). Chen et al., “Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation.” Cell, 58:1193—1198 (1989). DeCaprio et al., “The product of the retinoblastoma suscep tibility gene has properties of a cell cycle regulatory ele ment.” Cell, 58:1085—1095 (1989). Iggo and Lane, “Nuclear protein p68 is an RNA—dependent ATPase.” EMBO J., 8(6):1827—1831 (1989).
Moran et al., “Identi?cation of separate domains in the adenovirus E1A gene for immortiliZation activity and the activation of virus early genes.” Mol. and Cell. Biol., 6(10):3470—3480 (1986). Buchkovich et al., “The retinoblastoma protein is phospho rylated during speci?c phases of the cell cycle.” Cell, 58:1097—1105 (1989). Chen et al., “Identi?cation of a Human Homologue of Yeast Nuc2 Which Interacts With the Retinoblastoma Protein in a Speci?c Manner.” Cell Growth & Di?rer 6:199—210 (1995). BartholomeW and Ihle, “Retroviral insertions 90 kilobases proximal to the Evi—1 myeloid transforming gene activate transcription from the normal promoter.” Mol. Cell. Biol., 11(4):1820—1828 (1991). Morishita et al., “Expression of the Evi—1 Zinc ?nger gene in 32Dc13 myeloid cells blocks granulocytic differentiation in response to granulocyte colony—stimulating factor.” Mol. Cell. Biol, 12(1):183—189 (1992). Buyse et al., “The retinoblastoma protein binds to RIZ, a Zinc—?nger protein that shares an epitope With the adenovi rus E1Aprotein.”Proc. NatLAcad. Sci. USA, 92:4467—4471
(1995). Kreider et al., “Loss of erythropoietin responsiveness in erythroid progenitors due to expression of the Evi—1 myeloid—transforming gene.” Proc. Natl. Acad. Sci. USA, 90:6454—6458 (1993). Miyoshi et al., “t(8;21)breakpoints on chromosome 21 in acute myeloid leukemia are clustered Within a limited region of a single gene, AML1.” Proc. Natl. Acad. Sci. USA, 88:10431—10434 (1991). Nucifora et al., “Consistent intergenic splicing and produc tion of multiple transcripts betWeen AML1 at 21q22 and unrelated genes at 3q26 in (3;21) (q26;q22)translocations.” Proc. Natl. Acad. Sci. USA, 91:4004—4008 (1994). Morishita et al., “Unique expression of the human Evi—1 gene in an endometrial carcinoma cell line: sequence of cDNAs and structure of alternatively spliced transcripts.” Oncogene, 5:963—971 (1990). Lee et al., “Dual roles of the retinoblastoma protein in cell cycle regulation and neuron differentiation.” Genes & Development, 8:2008—2021 (1994). Garriga et al., “Migrations of the caenorhaba'itis elegans HSNs are regulated by egl—43, a gene encoding tWo Zinc ?nger proteins.” Genes & Development, 7:2097—2109 (1993). Turner et al., “Blimp—1, a novel Zinc ?nger—containing protein that can drive the maturation of B lymphocytes into immunoglobulin—secreting cells.” Cell, 77:297—306 (1994). Weinberg Robert A., “The retinoblastoma protein and cell cycle control.” Cell, 81:323—330 (1995). Morishita et al., “EVI—1 Zinc ?nger protein Works as a transcriptional activator via binding to a consensus sequence of GACAAGATAAGATAAN 1128 CTCATCTTC.” Onco gene, 10:1961—1967 (1995). Mitani et al., “Generation of the AML1—EVI—1 fusion gene in the t(3;21) (q26;q22) causes blastic crisis in chronic myelocytic leukemia.” EMBO J., 13(3):504—510 (1994). Rechsteiner Martin, “Regulation of enZyme levels by pro teolysis: the role of pest regions.” Aa'v. Enzyme. Regal, 27:135—151 (1988). Huang Shi, “Blimp—1 is the murine homolog of the human transcriptional repressor PRDI—BF1.” Cell, 78:9 (1994). Morishita et al., “Retroviral activation of a novel gene encoding a Zinc ?nger protein in IL—3—dependent myeloid leukemia cell lines.” Cell, 54:831—840 (1988).
![Page 3: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/3.jpg)
6,069,231 Page 3
Morishita et al., “The Evi—1 Zinc ?nger myeloid transform- Perkins et al., “Patterns of Evi—1 expression in embryonic ing gene is normally expressed in the kidney and in devel- and adult tissues Suggest that Evi_1 plays an important
regulatory role in mouse development.” Development, oping oocytes.” Oncogene, 5:1419—1423 (1990). 111;479_487 (1991)_
![Page 4: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/4.jpg)
U.S. Patent May 30, 2000 Sheet 1 0f 26 6,069,231
cow.“ com." cum." com“ one." 0mm omh cow omw own oow oNH
FE0440<442<<F248008F8088r004085000<<9609r0009r9600<200 00000 0U0<0U00040UOU0 000 8000 00UUOUO0U0£<0< 4.000 mvm mom mmv 00H mm mm
![Page 5: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/5.jpg)
![Page 6: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/6.jpg)
![Page 7: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/7.jpg)
U.S. Patent May 30, 2000 Sheet 4 0f 26 6,069,231
GAA'I'TCCCGG CTCACTGAAG CTTGGCACGT GCGCTCTGGA
ATATCTGAAT GATCTCAGTA CAATGAAGGA GTGCCTTTTC
CCT'I‘TCTACC CTGCCTCCTT GAAGCATGCA TTAGAGTCGT
T (SEQ ID NO: 94)
FIG. 1B
![Page 8: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/8.jpg)
![Page 9: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/9.jpg)
![Page 10: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/10.jpg)
U.S. Patent May 30, 2000 Sheet 7 0f 26 6,069,231
m .GE
msusnlmzm $5 60 who to H ._. K. ._..
I80 _ _ E \\\0 , _ i wot EQQETCN 3&5 ~._ wEmETcN m< mm
![Page 11: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/11.jpg)
U.S. Patent May 30, 2000 Sheet 8 0f 26 6,069,231
As‘ ‘2* [*1
010 50501050 5001M?)
5 6
FIG. 4 1234
7 $51M 5 i. :2 Egg 3mg 3 .. 5.15 m
PPL
B30"
12 3 4 5
FIG. 5A FIG. 5B
![Page 12: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/12.jpg)
U.S. Patent May 30, 2000 Sheet 9 0f 26 6,069,231
Em 1mm?
nmirci .m _. my NEIHWG ?wmwlm _. my NE
w pHb
FIG. 6
![Page 13: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/13.jpg)
U.S. Patent May 30, 2000 Sheet 10 0f 26 6,069,231
+211“
wwmhww wwwkmw m “THEM. hmmu
FIG. 7A FIG. 75 FIG. 7C
![Page 14: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/14.jpg)
U.S. Patent May 30, 2000 Sheet 11 0f 26 6,069,231
![Page 15: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/15.jpg)
U.S. Patent May 30, 2000 Sheet 12 0f 26 6,069,231
03% 00m ovm ooo omv own o:
![Page 16: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/16.jpg)
U.S. Patent May 30, 2000 Sheet 13 0f 26 6,069,231
ommm owhm ovum ONmN oovm ommm owHm ovoN oNmH oomH
![Page 17: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/17.jpg)
U.S. Patent May 30, 2000 Sheet 14 0f 26 6,069,231
cmmv oomv omoq owmm ovmm omhm Doom omvm comm ovmm ooom
![Page 18: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/18.jpg)
U.S. Patent May 30, 2000 Sheet 15 0f 26 6,069,231
02% 03m oumm oovm 33 0w 7... owom ommq 003 cm: 82 avg.
![Page 19: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/19.jpg)
U.S. Patent May 30, 2000 Sheet 16 0f 26 6,069,231
1. Clone SY
G GAG TGG GGG CCA GTC ACC CGG AGC CTT CAG CGC
E W G P V T R S L Q R
AGC ACC AAG CAG GAG CTG AAG GAc TTG CAG (95)
s T K Q E. L K D L Q (102)
2. Clone lY
GGG GCC GGC GAA ACA GCG GCG GCG GCG GCG GCC C'I'C
G A E E T A A A A A A L
GGT GCT CTG AGG CTG GGc CGG CGG GCG CGG (96)
G A L R L G R R A R (103)
— Number in parentheses is SEQ ID NO: .
FIG. 9B
![Page 20: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/20.jpg)
U.S. Patent May 30, 2000 Sheet 17 0f 26 6,069,231
GCIYACYXGCIAGCCTCACAAGCA'IGAAGHIITGKXCIGITCCTMCCIA SO A'IGA'IOCCXTI‘ TI‘IGICCCGI‘ AAA‘IGTIAAC ACICA'IGAAG CA'IACIXICGS lOO mmcmmmmmm 150 AACUIAAACCICXIEXAGICACCIWOXKBIGAGCTCIGGSAAGT 200 GIGFITGAGGCCITGZXIEICACICCITTTTTCIIATGIGRAATGIQTKE 250 WWWAAACIGTICCAATCAIGAAA 300 AWTGATTTIGIYAAAGIGCXRTTICCIKHCAGIGGIWICI'ICA 350 AGALEACACIITCIGIATCIGCUUGIGAAGAGAATEAACAA‘IYXAAAGIGT 400 GAAGRQIGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 450 AAAAAAAAAAAAAGQXImCCGC 474
FIG. 9C
![Page 21: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/21.jpg)
![Page 22: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/22.jpg)
![Page 23: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/23.jpg)
![Page 24: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/24.jpg)
![Page 25: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/25.jpg)
![Page 26: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/26.jpg)
![Page 27: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/27.jpg)
![Page 28: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/28.jpg)
![Page 29: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/29.jpg)
![Page 30: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/30.jpg)
![Page 31: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/31.jpg)
![Page 32: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/32.jpg)
![Page 33: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/33.jpg)
![Page 34: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/34.jpg)
![Page 35: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/35.jpg)
![Page 36: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/36.jpg)
![Page 37: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/37.jpg)
![Page 38: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/38.jpg)
![Page 39: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/39.jpg)
![Page 40: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/40.jpg)
![Page 41: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/41.jpg)
![Page 42: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/42.jpg)
![Page 43: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/43.jpg)
![Page 44: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/44.jpg)
![Page 45: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/45.jpg)
![Page 46: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/46.jpg)
![Page 47: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/47.jpg)
![Page 48: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/48.jpg)
![Page 49: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/49.jpg)
![Page 50: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/50.jpg)
![Page 51: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/51.jpg)
![Page 52: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/52.jpg)
![Page 53: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/53.jpg)
![Page 54: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/54.jpg)
![Page 55: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/55.jpg)
![Page 56: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/56.jpg)
![Page 57: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/57.jpg)
![Page 58: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/58.jpg)
![Page 59: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/59.jpg)
![Page 60: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/60.jpg)
![Page 61: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/61.jpg)
![Page 62: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/62.jpg)
![Page 63: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/63.jpg)
![Page 64: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/64.jpg)
![Page 65: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/65.jpg)
![Page 66: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/66.jpg)
![Page 67: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/67.jpg)
![Page 68: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/68.jpg)
![Page 69: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/69.jpg)
![Page 70: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/70.jpg)
![Page 71: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/71.jpg)
![Page 72: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/72.jpg)
![Page 73: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/73.jpg)
![Page 74: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/74.jpg)
![Page 75: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/75.jpg)
![Page 76: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/76.jpg)
![Page 77: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/77.jpg)
![Page 78: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/78.jpg)
![Page 79: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/79.jpg)
![Page 80: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/80.jpg)
![Page 81: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/81.jpg)
![Page 82: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/82.jpg)
![Page 83: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/83.jpg)
![Page 84: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/84.jpg)
![Page 85: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/85.jpg)
![Page 86: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/86.jpg)
![Page 87: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/87.jpg)
![Page 88: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/88.jpg)
![Page 89: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/89.jpg)
![Page 90: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/90.jpg)
![Page 91: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/91.jpg)
![Page 92: PR domain peptides](https://reader034.vdocument.in/reader034/viewer/2022052419/588c6b5a1a28ab69218b808a/html5/thumbnails/92.jpg)